Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

• Published in: Circulation. Cardiovascular genetics Vol. 8; no. 2; pp. 372 - 382
• Main Authors: Tardif, Jean-Claude, Rhéaume, Eric, Lemieux Perreault, Louis-Philippe, Grégoire, Jean C., Feroz Zada, Yassamin, Asselin, Géraldine, Provost, Sylvie, Barhdadi, Amina, Rhainds, David, L’Allier, Philippe L., Ibrahim, Reda, Upmanyu, Ruchi, Niesor, Eric J., Benghozi, Renée, Suchankova, Gabriela, Laghrissi-Thode, Fouzia, Guertin, Marie-Claude, Olsson, Anders G., Mongrain, Ian, Schwartz, Gregory G., Dubé, Marie-Pierre
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01.04.2015
• Subjects: Adenylyl Cyclases - genetics; Aged; Atherosclerosis - diagnostic imaging; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Carotid Intima-Media Thickness; Chromosomes, Human, Pair 16 - genetics; Female; Humans; Linkage Disequilibrium; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Sulfhydryl Compounds - administration & dosage; high-density lipoproteins; cholesteryl ester transfer protein; pharmacogenetics; dalcetrapib

BACKGROUND—Dalcetrapib did not improve clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%. These results differ from other evidence supporting high-density lipoprotein as a therapeutic target. Responses to dalcetrapib may vary according to patients’ genetic profile. ME...